A prospective multicenter, randomized, controlled clinical study on the efficacy and influencing factors of quadruple regimens comprising minocycline and ornidazole for eradication of Helicobacter pylori

A prospective multicenter, randomized, controlled clinical study on the efficacy and influencing factors of quadruple regimens comprising minocycline for eradication of Helicobacter pylori

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033717

Enrollment

Unknown

Registered

2020-06-10

Start date

2020-06-09

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infecion

Interventions

Group A:minocycline (100mg BID)+ ornidazole (500mg BID) + bismuth (220mg BID)+ esomeprazole (20mg BID) for 2 weeks

Group B:amoxillin (1000mg BID)+ clarithromycin (500mg BID)+ bismuth(220mg BID)+ esomeprazole (20mg BID) for 2 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients, aged between 18-70 years. 2. Patients who did not take antibiotics, bismuth and traditional Chinese medicine 4 weeks before treatment, and patients who took PPI, H2 receptor antagonists and other drugs that affect HP activity 2 weeks before treatment; 3. Patients who were diagnosed as HP positive by C13 or C14 urea breath test, rapid urease test and histopathology, and who had not received HP eradication treatment before; 4. Informed and agreed to participate in the study, patients with complete medical records and follow-up records.

Exclusion criteria

Exclusion criteria: 1. With severe heart, lung, and kidney dysfunction and low immunity; 2. Patients with drug allergy contraindications; 3. Persons with mental illness or communication difficulties; 4. Pregnancy, lactation; 5. Patients with organic diseases such as gastrointestinal tumor and gastrointestinal hemorrhage.

Design outcomes

Primary

Measure	Time frame
eradication rate;	—

Secondary

Measure	Time frame
antibiotic resistance of Helicobacter pylori;adverse reaction;	—

Countries

China

Contacts

Public ContactZhihui Lin

Fujian Provincial Hospital

lzh54321@139.com+86 13799371368

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026